Medscape Medical NewsAll articles

Ziostation2

Ziosoft, Inc. • Radiology • 10/09/2018

510(k)IEC 62304 Class B
FDA Summary PDF

Device Purpose

Ziostation2 is an advanced medical image processing software designed to assist clinicians by providing comprehensive tools for viewing, quantifying, and managing multi-modality radiological images, including specialized analyses for pulmonary and cardiac conditions. Its methodology incorporates established image processing algorithms for features like LAA analysis, lung lobe extraction, virtual bronchoscopy, CT lung resection planning, and MR myocardial T1 mapping, all integrated into a networkable DICOM-compliant system for enhanced diagnostic support and validated through rigorous testing.

Summary

Ziostation2 is an image processing application software designed for installation on customer-owned hardware, facilitating the management and analysis of a wide array of medical images. It supports various image types including CT, MRI, Ultrasound, Digital X-ray, X-ray Angiography, PET, SPECT, Nuclear Medicine, and Mammography, among others. The system is networkable, allowing for resource sharing, and receives image data from modalities or Picture Archiving and Communication Systems (PACS) via network or media. Core functionalities include DICOM image management encompassing data retrieval, storage, querying, listing, viewing, quantification, manipulation, communication, and printing. It is intended for use by trained medical professionals as a supplementary tool to aid in the interpretation of radiological images and the analysis of anatomy, physiology, and pathology, with specific restrictions on using lossy compressed mammographic images for primary interpretation. This version of Ziostation2 introduces several enhanced and new functionalities building upon its established image processing capabilities. These include LAA (Left Atrial Appendage) analysis with Goddard score classification, lung lobe extraction for detailed pulmonary assessment, and an Advanced MPR (Multi-Planar Reformation) Batch for improved workflow. New significant additions are Virtual Bronchoscopy, which provides a visual pathway to target areas without direct connection to a physical bronchoscope, and CT Lung Resection Planning, which assists in surgical preparation by extracting anatomical structures like bronchi and lesions and proposing resection plans. Furthermore, MR Myocardial T1 Mapping capabilities have been added for post-process analysis of cardiac MR images. The system's methodology relies on established image processing algorithms and techniques, successfully validated through integration, verification, and regression testing, with potential hazards addressed via a formal risk management process.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

Medical Image ProcessingDICOM ManagementRadiological Image AnalysisCT Lung AnalysisVirtual BronchoscopyMR Myocardial T1 MappingImage QuantificationPACS IntegrationClinical Decision SupportMulti-modality Imaging

Device Metadata

Submission Number
K181892
Company
Ziosoft, Inc.
Panel
Radiology
Product Code
N/A
Data Type
Images
Clinical Function
Assessment
AI Function
Analysis
AI Subclass
quantification/feature localization

Relevant Clinical Questions

  • Q1. What specific algorithms are employed for the LAA analysis (Goddard score) and lung lobe extraction, and how has their accuracy been validated against gold standards?; How does the Virtual Bronchoscopy module generate its navigational pathways, and what is the typical processing time for creating a virtual bronchoscopic view from a CT dataset?; For the CT Lung Resection Planning tool, what are the key parameters and user inputs required to generate a resection proposal, and how does it account for variations in patient anatomy or pathology?; Regarding MR Myocardial T1 Mapping, what are the supported T1 mapping sequences and how does the software handle potential motion artifacts or co-registration challenges with other cardiac MR sequences?; Given the wide range of supported image modalities, what are the quality control mechanisms within Ziostation2 to ensure consistent image display and accurate quantification across different types of imaging data and hardware configurations?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score20/100
SBOM Evidence⚠ Not mentioned in summary
Cyber Risk Assessment⚠ Not mentioned in summary
Postmarket Plan⚠ Not mentioned in summary
§524B ApplicableNo

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials
- Not detected
ML-BOMMachine Learning Bill of Materials(algorithm, dataset)
✓ Detected
SaaSBOMSoftware-as-a-Service Bill of Materials(network)
✓ Detected
HBOMHardware Bill of Materials(hardware)
✓ Detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials(configuration)
✓ Detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of ML-BOM, SaaSBOM, HBOM, OBOM detected in AI-generated device summary.

• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.

• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.

• Not detected in AI-generated device summary: SBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
Ziostation2 - Ziosoft, Inc. | ESL FDA AI Device Intelligence